Published in J Clin Invest on July 11, 2013
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma | NCT00683670
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (2015) 4.29
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Soluble mediators regulating immunity in early life. Front Immunol (2014) 0.99
Insufficient interleukin-12 signalling favours differentiation of human CD4(+) and CD8(+) T cells into GATA-3(+) and GATA-3(+) T-bet(+) subsets in humanized mice. Immunology (2014) 0.95
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91
Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90
Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med (2014) 0.85
microRNAs function in CD8+T cell biology. J Leukoc Biol (2015) 0.83
Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun (2016) 0.82
Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol (2015) 0.82
Dendritic cell-based immunotherapy. Cell Res (2016) 0.81
Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive. Br J Cancer (2014) 0.81
Dendritic cell-based vaccines: Shining the spotlight on signal 3. Oncoimmunology (2013) 0.80
Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis (2015) 0.80
Dendritic Cells and Cancer Immunity. Trends Immunol (2016) 0.80
A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination. Oncotarget (2015) 0.79
The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer (2014) 0.78
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. Front Immunol (2016) 0.78
The translation of cancer genomics: time for a revolution in clinical cancer care. Genome Med (2014) 0.78
Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. J Invest Dermatol (2015) 0.76
Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials (2017) 0.76
CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology (2014) 0.75
mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncoimmunology (2016) 0.75
Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther (2014) 0.75
Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination. Mediators Inflamm (2016) 0.75
Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. Oncoimmunology (2016) 0.75
Glycyrrhiza uralensis water extract enhances dendritic cell maturation and antitumor efficacy of HPV dendritic cell-based vaccine. Sci Rep (2017) 0.75
Radiation Inhibits Interleukin-12 Production via Inhibition of C-Rel through the Interleukin-6/ Signal Transducer and Activator of Transcription 3 Signaling Pathway in Dendritic Cells. PLoS One (2016) 0.75
Immunogenicity is preferentially induced in sparse dendritic cell cultures. Sci Rep (2017) 0.75
IL-1β, IL-8, and Matrix Metalloproteinases-1, -2, and -10 Are Enriched upon Monocyte-Breast Cancer Cell Cocultivation in a Matrigel-Based Three-Dimensional System. Front Immunol (2017) 0.75
Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system. Vaccine (2017) 0.75
Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion. PLoS One (2017) 0.75
Comparative study of dendritic cells matured by using IL-1β, IL-6, TNF-α and prostaglandins E2 for different time span. Exp Ther Med (2017) 0.75
Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists. Cancer Immunol Immunother (2017) 0.75
Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology (2017) 0.75
Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. Cancer J (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 15.65
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Taking dendritic cells into medicine. Nature (2007) 11.82
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol (2010) 6.85
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol (2005) 6.81
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 6.11
Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol (1995) 6.09
Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 5.48
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Decisions about dendritic cells: past, present, and future. Annu Rev Immunol (2011) 4.26
IL-12 family cytokines: immunological playmakers. Nat Immunol (2012) 3.12
Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol (1999) 3.10
Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med (1994) 3.02
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66
Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J Immunol (2001) 2.56
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 2.52
Twelve immunotherapy drugs that could cure cancers. Immunol Rev (2008) 2.45
Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood (1995) 2.36
Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood (2003) 2.17
Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol (2009) 2.15
High-level IL-12 production by human dendritic cells requires two signals. Int Immunol (1998) 2.15
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol (2009) 2.08
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood (2012) 1.94
Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol (1996) 1.74
Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res (1999) 1.73
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol (2003) 1.72
A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J Exp Med (2004) 1.71
Harnessing the immune system to treat cancer. J Clin Invest (2007) 1.57
Duration, combination and timing: the signal integration model of dendritic cell activation. Trends Immunol (2007) 1.55
Breaking free of sample size dogma to perform innovative translational research. Sci Transl Med (2011) 1.41
Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One (2011) 1.38
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother (2008) 1.37
Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo. J Immunol (1999) 1.35
Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol (2003) 1.34
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res (2011) 1.29
A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood (2000) 1.26
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res (2009) 1.25
Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol (2007) 1.24
Dendritic cells in cancer immunotherapy. Eur J Immunol (2010) 1.19
Interferon regulatory factor 3-dependent responses to lipopolysaccharide are selectively blunted in cord blood cells. Blood (2007) 1.17
Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer (1999) 1.16
Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res (2007) 1.13
The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol (2010) 1.06
Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res (1990) 1.05
A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res (2010) 1.05
Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. Blood (2011) 1.04
Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res (2008) 1.03
Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res (2005) 0.93
Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res (2006) 0.88
Amino-terminal extended peptide single-chain trimers are potent synthetic agonists for memory human CD8+ T cells. J Immunol (2012) 0.87
CD40 regulates human dendritic cell-derived IL-7 production that, in turn, contributes to CD8(+) T-cell antigen-specific expansion. Immunol Cell Biol (2008) 0.87
Cellular based cancer vaccines: type 1 polarization of dendritic cells. Curr Med Chem (2012) 0.86
Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy. J Immunother (2009) 0.84
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Concern The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist (2003) 3.36
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood (2012) 2.77
Improving follow-up for children with asthma after an acute Emergency Department visit. J Pediatr (2004) 2.29
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol (2002) 2.27
Porous implant exposure: Incidence, management, and morbidity. Ophthal Plast Reconstr Surg (2007) 2.12
Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol (2003) 2.11
US breast cancer mortality trends in young women according to race. Cancer (2014) 2.07
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07
Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol (2003) 1.85
Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics (2004) 1.76
Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer (2005) 1.68
Ocular melanoma: a review and the relationship to cutaneous melanoma. Arch Dermatol (2003) 1.67
Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause (2010) 1.56
Psychological factors related to delay in consultation for cancer symptoms. Psychooncology (2005) 1.55
Positive margin rates following breast-conserving surgery for stage I-III breast cancer: palpable versus nonpalpable tumors. J Surg Res (2012) 1.53
Predictors of primary breast abscesses and recurrence. World J Surg (2009) 1.51
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest (2012) 1.49
A tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol (2005) 1.47
Perioperative outcomes and complications of laparoscopic ventral hernia repair. Surgery (2005) 1.45
Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res (2007) 1.45
Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res (2011) 1.42
Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res (2006) 1.41
Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res (2006) 1.35
2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res (2003) 1.34
Hospital readmissions for childhood asthma: a 10-year metropolitan study. Am J Respir Crit Care Med (2003) 1.32
Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood (2006) 1.29
Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J Surg Oncol (2009) 1.27
Disparities related to socioeconomic status and access to medical care remain in the United States among women who never had a mammogram. Cancer Causes Control (2003) 1.24
Targeted therapies for cancer 2004. Am J Clin Pathol (2004) 1.23
In vivo photoacoustic microscopy of human cutaneous microvasculature and a nevus. J Biomed Opt (2011) 1.20
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther (2012) 1.20
Handheld photoacoustic microscopy to detect melanoma depth in vivo. Opt Lett (2014) 1.19
Down-regulation of Rap1GAP via promoter hypermethylation promotes melanoma cell proliferation, survival, and migration. Cancer Res (2009) 1.19
Factors affecting residency rank-listing: a Maxdiff survey of graduating Canadian medical students. BMC Med Educ (2011) 1.17
Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg (2009) 1.16
Central nervous system cancers. J Natl Compr Canc Netw (2011) 1.13
Chronic itch development in sensory neurons requires BRAF signaling pathways. J Clin Invest (2013) 1.13
Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases. Clin Cancer Res (2009) 1.12
Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn (2003) 1.12
Treatment and outcomes of patients with primary breast sarcoma. Am J Surg (2008) 1.07
The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci (2006) 1.06
Metastatic melanoma - a review of current and future treatment options. Acta Derm Venereol (2015) 1.05
Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg (2014) 1.03
Correlates of fear of cancer recurrence in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat (2011) 1.02
Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol Clin (2007) 1.01
Asthma coaching in the pediatric emergency department. Acad Emerg Med (2006) 1.00
A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer. Breast Cancer Res Treat (2010) 1.00
Scientific Presentation Award: The combination of axillary ultrasound and ultrasound-guided biopsy is an accurate predictor of axillary stage in clinically node-negative breast cancer patients. Am J Surg (2008) 0.99
DNA ploidy and cell cycle analysis in breast cancer. Am J Clin Pathol (2003) 0.98
In vivo functional photoacoustic microscopy of cutaneous microvasculature in human skin. J Biomed Opt (2011) 0.98
Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. Am J Surg (2010) 0.98
Accuracy of perceived risk of recurrence among patients with early-stage breast cancer. Cancer Epidemiol Biomarkers Prev (2010) 0.97
Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol (2011) 0.97
Practices of unregulated tanning facilities in Missouri: implications for statewide legislation. Pediatrics (2013) 0.96
HER-2/neu testing in breast cancer. Am J Clin Pathol (2003) 0.95
Distinct and nonoverlapping roles for pRB and cyclin D:cyclin-dependent kinases 4/6 activity in melanocyte survival. Proc Natl Acad Sci U S A (2003) 0.95
Metastatic disease to the breast: the Washington University experience. World J Surg Oncol (2007) 0.95
Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol (2011) 0.94
Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecol Oncol (2005) 0.94
Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol (2009) 0.93
A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat (2009) 0.93
Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione. J Nucl Med (2012) 0.92
Chemosensitizing and cytotoxic effects of 2-deoxy-D-glucose on breast cancer cells. J Cancer Res Ther (2009) 0.90
Complications of supramid orbital implants. Ophthal Plast Reconstr Surg (2003) 0.90
Assessment of cellular proliferation in tumors by PET using 18F-ISO-1. J Nucl Med (2013) 0.90
Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol (2008) 0.90
Breast cancer in elderly women (≥ 80 years): variation in standard of care? J Surg Oncol (2010) 0.89
Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol (2012) 0.89
Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging. Am J Clin Pathol (2003) 0.88
The impact of breast MRI on surgical decision-making: are patients at risk for mastectomy? J Surg Oncol (2009) 0.88
Sex differences in responding to rectal cancer symptoms. Psychol Health (2008) 0.88
Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn (2004) 0.88
CD40 regulates human dendritic cell-derived IL-7 production that, in turn, contributes to CD8(+) T-cell antigen-specific expansion. Immunol Cell Biol (2008) 0.87
Shared management of a rare necrotizing soft tissue infection of the breast. Breast J (2009) 0.87
Amino-terminal extended peptide single-chain trimers are potent synthetic agonists for memory human CD8+ T cells. J Immunol (2012) 0.87
Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides. J Biol Chem (2008) 0.87
Trait anxiety as an independent predictor of poor health-related quality of life and post-traumatic stress symptoms in rectal cancer. Br J Health Psychol (2009) 0.86
Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer. Int J Mol Sci (2013) 0.86
Sirolimus-induced leukocytoclastic vasculitis. Transplantation (2002) 0.85
Innate immune interleukin-1 receptor-associated kinase 4 exacerbates viral myocarditis by reducing CCR5(+) CD11b(+) monocyte migration and impairing interferon production. Circulation (2013) 0.84
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol (2008) 0.84
Impact of neoadjuvant chemotherapy on rate of tissue expander/implant loss and progression to successful breast reconstruction following mastectomy. Am J Surg (2008) 0.83
Oligodendrogliomas in children. J Neurooncol (2011) 0.82
Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas. Neuro Oncol (2013) 0.82
Impact of multiple caregiving roles on elevated depressed mood in early-stage breast cancer patients and same-age controls. Breast Cancer Res Treat (2009) 0.81
Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol (2002) 0.81